This PET imaging study performed in LRRK2-NMCs found reduced putaminal 18F-DOPA uptake in five out of eight LRRK2-NMCs as previously reported in subjects without manifest PD carrying different subtypes of LRRK2 mutations [9]. This evidence concerns the gene LRRK2 and Parkinson disease.